Dr. Majid Golkar, the managing director of the company said that the project was supported by Presidential Science and Technology deputy Headquarters for Development of Stem Cell Technologies.
“Epidermal growth factor is a naturally occurring protein in the cells and stimulates growth of many cells including fibroblasts and epidermic and skin cells; EGF had been purchased in higher prices from foreign developers before, while the domestically developed EGF equals the foreign EGF in quality and is supplied in very low prices,” he said.
“The project kicked off 4 years ago as a research project under the auspices of the Presidential Science and Technology deputy Headquarters for Development of Stem Cell Technologies; in last two years, the product was prepared for semi-industrial production level,” Golkar asserted. “EGF is the most popular growth factor, mainly in cell cultures and biotechnology laboratories annually; the production of the growth factor would help save additional costs of importing the product,” he asserted.
Golkar pointed to a call for all cell cultures, tissue bioengineering centers, universities, research centers, and knowledge-based companies to order Iranian developed growth factor in high quality and affordable prices. “EGF has applications in skin medications, diabetes lesion treatment, and burning healing; we hope that the Presidential Science and Technology deputy supports the EGF industrial production,” he suggested.
“With 6 million Iranians suffering from diabetes, 2-5 per cent of whom suffer from foot lesions, the EGF would be crucial in treatment of these patients with efficiency in healing foot lesions confirmed by much research around the world,” Golkar added, expressing hope that the low price of the product would bring a little solace to the patients and play a role in improving their quality of life.
SH
MNA
END
Your Comment